PlaqueTec Raises $5M To Advance Cardiovascular Disease Diagnostics Using Liquid Biopsy Technology

The funding will support the expansion of PlaqueTec’s proprietary cardiovascular data platform, BioCarta, which compiles unique intracoronary proteomic and clinical datasets.

This platform aims to enable a new site-of-disease approach for better understanding and stratifying inflammatory risk in cardiovascular disease, improving diagnosis accuracy and helping guide more targeted therapeutic strategies for better patient outcomes.

PlaqueTec’s BioCarta database is built using proteomic data from patient samples collected in the BIOPATTERN trial through its intracoronary liquid biopsy technology.

By leveraging the coronary concentration gradient, the device collects biomarkers directly from the site of plaque formation, generating insights that cannot be captured through conventional blood sampling.

Read Also - Austria’s Noreja Raises €1.1M To Scale AI Process Intelligence Platform

The ongoing BIOPATTERN trial continues to expand this dataset across a growing patient population with early analysis identifying multiple potential therapeutic targets within key sub-groups of coronary artery disease patients.

This positions BioCarta as a strategic data asset for collaboration and licensing with pharmaceutical companies focused on cardiovascular drug development.

PlaqueTec is also in active discussions with pharma and biotech partners seeking to use its intracoronary insights to improve target selection and patient stratification in next-generation cardiovascular therapies.

Martin Stapleton, Chairman, PlaqueTec commented: “The decision by our existing shareholders to reinvest and to do so at a level that exceeded our target, speaks directly to their confidence in what PlaqueTec's data is revealing about cardiovascular disease. We are building something genuinely differentiated: a high-resolution, intracoronary data asset that is poised to underpin the next generation of cardiovascular therapeutics. This round validates that strategy and gives us the runway to prove it.”

About PlaqueTec

PlaqueTec is a medtech company focused on advancing the understanding of coronary artery disease by studying its biological mechanisms. The company aims to improve precision medicine approaches for atherosclerosis by generating deeper insights into disease drivers and enabling more targeted cardiovascular treatments.